Edward J. Dulac III

2020

In 2020, Edward J. Dulac III earned a total compensation of $5.7M as Chief Financial Officer at Fate Therapeutics.

Compensation breakdown

Bonus$137,917
Non-Equity Incentive Plan$75,833
Option Awards$3,786,529
Salary$142,500
Stock Awards$1,420,800
Other$120,000
Total$5,683,579

Dulac received $3.8M in option awards, accounting for 67% of the total pay in 2020.

Dulac also received $137.9K in bonus, $75.8K in non-equity incentive plan, $142.5K in salary, $1.4M in stock awards and $120K in other compensation.

Rankings

In 2020, Edward J. Dulac III's compensation ranked 1,885th out of 13,090 executives tracked by ExecPay. In other words, Dulac earned more than 85.6% of executives.

ClassificationRankingPercentile
All
1,885
out of 13,090
86th
Division
Manufacturing
734
out of 5,621
87th
Major group
Chemicals And Allied Products
264
out of 2,254
88th
Industry group
Drugs
222
out of 1,954
89th
Industry
Biological Products, Except Diagnostic Substances
64
out of 411
84th
Source: SEC filing on April 21, 2021.

Dulac's colleagues

We found four more compensation records of executives who worked with Edward J. Dulac III at Fate Therapeutics in 2020.

2020

J Wolchko

Fate Therapeutics

Chief Executive Officer

2020

Bahram Valamehr

Fate Therapeutics

Chief Research and Development Officer

2020

Cindy Tahl

Fate Therapeutics

General Counsel

2020

Daniel Shoemaker

Fate Therapeutics

Chief Scientific Officer

News

In-depth

You may also like